Home
 /
Papers
 /
Genetics
 /
Genome-scale mapping of variant, enhancer and gene function in primary human CD4+ T cells
Preprint
Open access
V1
Top 1% · Validated by QED

Genome-scale mapping of variant, enhancer and gene function in primary human CD4+ T cells

Dewi P. I. Moonen, Annique Claringbould, Andreas R. Gschwind +17 more
March 2026
 ·
bioRxiv
 ·
DOI 
10.64898/2026.03.09.710372
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Genetics this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

By achieving genome-wide Perturb-seq in primary human CD4+ T cells, this work solves a core bottleneck in human genetics—converting noncoding GWAS variants into mechanistic gene networks—and reveals actionable disease pathways at unprecedented scale.

Author perspective

What is the most important insight, discovery, or finding from your paper that you would like other scientists to know?
“

For years we've stared at GWAS hits, knowing these variants matter but unable to say how. What I am excited about is that we can finally characterize them experimentally and at sufficient depth. We've done that for autoimmune diseases, and the biology surprised us: one might expect hundreds of idiosyncratic mechanisms, one per locus, but instead, the variants converged onto a set of shared regulatory programs. That convergence is what gives hope therapeutically. Mechanism-per-locus has long been the missing input for turning human genetics into drugs, and we can now supply it at scale." by Daniel Schraivogel, co-corresponding author.

”
Daniel Schraivogel
&
Lars M. Steinmetz

QED claims analysis

Summary

Systematic perturbation of 1,032 immune disease-associated cis-regulatory elements and 7,664 genes in primary human CD4+ T cells establishes complete variant-to-CRE-to-gene-to-network regulatory cascades, revealing that dispersed disease variants converge on both shared immune programs and disease-specific pathways through enhancer-mediated gene regulation that propagates to 56% of the transcriptome within two regulatory connections.

See full analysis
Main Claim 1 –

Multi-stage variant-to-network mapping in primary CD4+ T cells

Main Claim 2 –

TAP-seq maps 626 cis CRE–gene interactions in CD4+ T cells

Supporting evidence

  • CRE–gene link predictions validate 13-fold better; eQTLs 35%
Main Claim 3 –

Chromatin and Hi-C integration yields 106 enhancer-like CRE–gene links

Supporting evidence

  • Enhancer-like CRE–gene links enriched in CD4+ T cell eQTLs
Main Claim 4 –

Genome-wide Perturb-seq maps CD4+ T cell networks with 79% knockdown

Supporting evidence

  • Promoter-screen networks enriched for cis-trans eQTLs and DoRothEA targets
  • TAP-seq detects weak CRE effects more sensitively than Perturb-seq
  • Factor analysis identifies JAK-STAT, IL-2 response, and regulatory programs

Abstract

CD4+ T cells harbor a disproportionate enrichment of immune disease risk loci and represent the primary cellular context for immune disease biology, yet the genes and regulatory programs these variants affect remain largely unknown. We combined targeted Perturb-seq of 1,032 cis-regulatory elements (CREs) overlapping 4,724 variants across 14 immune diseases with genome-wide Perturb-seq of all expressed genes in primary human CD4+ T cells, spanning 4.1 million cells. We identified 626 CRE-gene pairs, and connected CRE targets to downstream regulatory cascades. At the TYK2 and DEXI/CLEC16A loci, we resolved target genes and linked noncoding variants to inflammatory and metabolic programs. Across diseases, we revealed that dispersed variants converged on shared and disease-specific programs. Our work provides a framework for tracing variant-to-CRE-to-gene-to-network in disease-relevant primary cells.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?